EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Bioequivalence and Safety of Two Oseltamivir Phosphate for Oral Suspension in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open‑Label, Single‑Dose, Crossover Study

Yu Peng, Ming Zhou, Hegui Yan, Zhixiang Pan, Yiyi Wang, Shuang Wei, Guan Liu

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.1612 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Yu Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trial Centre, Wuhan Institute of Tuberculosis Prevention and Control, Wuhan Pulmonary Hospital, Wuhan, China. Hauptthemen laut MEDLINE: Oseltamivir, Fasting, Antiviral Agents. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Beijing Chengji Pharmaceutical Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This randomized, open‐label, single‐dose crossover study evaluated the bioequivalence of a Chinese‐manufactured oseltamivir phosphate oral suspension (7.5 mg/12.5 mL) against Tamiflu under fasting and fed conditions. A total of 42 healthy Chinese adults were enrolled in each group, with 39 completing the fasting group (3 withdrew) and 40 completing the fed group (1 withdrew in washout, 1 lost to follow‐up). Plasma concentrations of oseltamivir and its active metabolite oseltamivir carboxylate were measured via LC‐MS/MS, and pharmacokinetic parameters were calculated using non‐compartmental models. The 90% confidence intervals of key parameters fell within the 80.00‐125.00% range, confirming bioequivalence. No serious adverse events occurred, indicating similar safety profiles. The test formulation is bioequivalent to Tamiflu under both fasting and fed conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OseltamivirFastingAntiviral AgentsHumansCross-Over StudiesAdultTherapeutic EquivalencyMaleFemaleAdministration, OralYoung AdultHealthy VolunteersSuspensionsChinaTandem Mass SpectrometryMiddle AgedEast Asian People

Stichwörter der Autor:innen

bioequivalencehealthy subjectsoseltamivir phosphate for oral suspensionpharmacokineticssafety

Substanzen

OseltamivirAntiviral AgentsSuspensionsoseltamivir carboxylate

Autor:innen und Institutionen

  • Phase I Clinical Trial Centre, Wuhan Institute of Tuberculosis Prevention and Control, Wuhan Pulmonary Hospital, Wuhan, China.

Förderung

  • Beijing Chengji Pharmaceutical Co., Ltd

Zitieren

APA

Peng, Y., Zhou, M., Yan, H., Pan, Z., Wang, Y., Wei, S., & Liu, G. (2026). Bioequivalence and Safety of Two Oseltamivir Phosphate for Oral Suspension in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open‑Label, Single‑Dose, Crossover Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1612

Vancouver

Peng Y, Zhou M, Yan H, Pan Z, Wang Y, Wei S, et al. Bioequivalence and Safety of Two Oseltamivir Phosphate for Oral Suspension in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open‑Label, Single‑Dose, Crossover Study. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.1612

BibTeX
@article{Peng2026,
  author = {Peng, Yu and Zhou, Ming and Yan, Hegui and Pan, Zhixiang and Wang, Yiyi and Wei, Shuang and Liu, Guan},
  title = {Bioequivalence and Safety of Two Oseltamivir Phosphate for Oral Suspension in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open‑Label, Single‑Dose, Crossover Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.1612}
}
Kostenlos starten →